Showing results (521-530 of 579) with videos related to
Sort By:
Pageof 58
Blood Advances|May 27, 2026
Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AMLNicholas J Short, Hagop M Kantarjian, Naval G Daver, et al.Blood Advances|August 16, 2022
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndromeCourtney D DiNardo, Sangeetha Venugopal, Curtis Lachowiez, et al.Cancer|August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutationSankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.BMJ Open|March 21, 2024
Comprehensive quality assessment for aphasia rehabilitation after stroke: protocol for a multicentre, mixed-methods studySam Harvey, Marissa Stone, Sally Zingelman, et al.Blood|April 3, 2025
Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML OutcomesPatrick K Reville, Bofei Wang, Jennifer Marvin-Peek, et al.Blood Advances|May 9, 2022
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapseNicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.Leukemia & Lymphoma|April 20, 2022
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemiaNicholas J Short, Gautam Borthakur, Naveen Pemmaraju, et al.Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.Blood|March 29, 2024
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALLYaqi Zhao, Nicholas J Short, Hagop M Kantarjian, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2024
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AMLNicholas J Short, Naval Daver, Courtney D Dinardo, et al.Pageof 58